BCL2 and lupus nephritis: Educators stated, “for hypertension certain patient populations respond better to thiazide diuretics and calcium channel blockers versus ACEi or ARB’s.” Other explanations to adjust medication management based on race included: epilepsy (“for a person of Asian heritage”), heart failure (“black patients have been shown to have lower mortality when taking a medication called Bidil”), multiple myeloma (“venetoclax that is a bcl-2 inhibitor that may be more effective in AA”), and lupus nephritis (persons “who self-identify [sic] as black have a better response to rituximab”).